MEDEXUS PHARMACEUTICALS INC (MDP.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:MDP - CA58410Q2036 - Common Stock
MDP.CA Key Statistics, Chart & Performance
The current stock price of MDP.CA is 2.71 CAD. In the past month the price decreased by -5.9%. In the past year, price decreased by -1.45%.
MDP.CA Latest News, Press Relases and Analysis
MDP.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.63 | 3.24B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 1.65B | ||
| CRON.CA | CRONOS GROUP INC | 23.2 | 1.33B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.32 | 908.43M | ||
| DHT-U.CA | DRI HEALTHCARE TRUST | 5.14 | 637.07M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 600.70M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 575.02M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 401.55M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 15.89 | 374.23M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 364.58M | ||
| HITI.CA | HIGH TIDE INC | N/A | 322.75M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 302.24M |
Related stock screener links
About MDP.CA
Company Profile
Medexus Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The company is headquartered in Toronto, Ontario and currently employs 91 full-time employees. The company went IPO on 2012-03-03. The firm has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. The company operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Company Info
MEDEXUS PHARMACEUTICALS INC
10 King Street East, Suite 600
TORONTO ONTARIO H3E 1A2 CA
CEO: Kenneth d’Entremont
Employees: 91
Phone: 18774225242
MEDEXUS PHARMACEUTICALS INC / MDP.CA FAQ
What does MEDEXUS PHARMACEUTICALS INC do?
Medexus Pharmaceuticals, Inc. engages in the development and commercialization of pharmaceutical products and treatment solutions focusing on therapeutic areas of oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. The company is headquartered in Toronto, Ontario and currently employs 91 full-time employees. The company went IPO on 2012-03-03. The firm has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. The company operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Can you provide the latest stock price for MEDEXUS PHARMACEUTICALS INC?
The current stock price of MDP.CA is 2.71 CAD. The price increased by 0.37% in the last trading session.
What is the dividend status of MEDEXUS PHARMACEUTICALS INC?
MDP.CA does not pay a dividend.
What is the ChartMill technical and fundamental rating of MDP stock?
MDP.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the Price/Earnings (PE) ratio of MEDEXUS PHARMACEUTICALS INC (MDP.CA)?
The PE ratio for MEDEXUS PHARMACEUTICALS INC (MDP.CA) is 271. This is based on the reported non-GAAP earnings per share of 0.01 and the current share price of 2.71 CAD.
Would investing in MEDEXUS PHARMACEUTICALS INC be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on MDP.CA.
MDP.CA Technical Analysis
MDP.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to MDP.CA. MDP.CA has only an average score on both its financial health and profitability.
MDP.CA Financial Highlights
Over the last trailing twelve months MDP.CA reported a non-GAAP Earnings per Share(EPS) of 0.01. The EPS decreased by -88.89% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 0.37% | ||
| ROA | 0.25% | ||
| ROE | 0.73% | ||
| Debt/Equity | 0 |
MDP.CA Forecast & Estimates
9 analysts have analysed MDP.CA and the average price target is 6.3 CAD. This implies a price increase of 132.55% is expected in the next year compared to the current price of 2.71.
For the next year, analysts expect an EPS growth of -115.78% and a revenue growth -5.78% for MDP.CA